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Verrucous carcinoma is an unusual, non-metastasizing, 
distinct variant of squamous cell carcinoma composed of 
four subtypes according to the site of occurrence: oral type, 
anogenital type, plantar type, and other cutaneous sites. Oral 
type verrucous carcinoma usually shows slow progression 
with a low incidence of metastases. Treatment of verrcous 
carcinoma is challenging; multiple medical and surgical 
therapies are often attempted, with limited success. We 
reported on 2 cases of verrucous carcinoma of the lip treated 
with topical imiquimod and debulking therapy. (Ann 
Dermatol 23(S1) S68∼S71, 2011)
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INTRODUCTION
Verrucous carcinoma is an unusual, distinct variant of 
squamous cell carcinoma, which was first reported by 
Ackerman in 1948
1. Verrucous carcinomas consist of oral 
tumors on the buccal mucosa, which have been referred 
to as oral florid papillomatosis
2. These tumors may be 
clinically mistaken for giant warts, and both clinical and 
histological diagnosis must be established. Malignant 
transformation of verrucous carcinoma into squamous cell 
carcinoma has been reported in 30∼50% of cases
3; 
however, no clear guidelines for effective and safe 
management of this disease are currently available. Here, 
we report on two cases of verrucous carcinoma of the 
lower lip, which were treated with a combination of 
topical imiquimod (Aldara
Ⓡ) and debulking therapy.
CASE REPORT
Case 1
A 70-year-old male patient presented with an extensive 
verrucous, hyperkeratotic tumor on the central aspect of 
his lower lip (Fig. 1A). The tumor had been growing for 1 
month. The patient was a smoker and a social alcohol 
drinker. However, his history of trauma to the lesion was 
unremarkable and he had no past medical history or 
family history of similar lesions or other skin diseases. 
Physical examination revealed an exophytic verrucous 
yellowish-to-whitish tumor measuring approximately 4 cm 
in diameter. The patient complained of mild tenderness 
on the lesion and the tumor was firm upon palpation. No 
lymphadenopathy was detected on the neck or sublingual 
area.
Microscopic examination of a punch biopsy specimen 
revealed an endophytic epidermal proliferation with 
bulbous and blunted projections composed of large well- 
differentiated squamous epithelial cells extending into the 
reticular dermis (Fig. 2A). Cellular pleomorphism was 
minimal and mitotic activity was confined to the basal Treatment of Verrucous Carcinoma of the Lower Lip with Topical Imiquimod (Aldara
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Fig. 2. (A) A biopsy specimen revealed the presence of an endophytic epidermal proliferation with bulbous, blunted projections 
composed of large, well-differentiated, squamous epithelial cells extending into the reticular dermis (H&E, ×20). (B) Cellular 
pleomorphism was minimal and mitotic activity was confined to the basal layer (H&E, ×200).
Fig. 1. (A) Extensive verrucous, 
hyperkeraotic tumor on the central 
aspect of the lower lip. (B) After 
treatment, all skin lesions 
disappeared.
layer (Fig. 2B). Based on these findings, the patient was 
diagnosed with verrucous carcinoma. Carbon dioxide 
laser treatment was then performed following tumescent 
local anesthesia using lidocaine 0.2%.
After 10 days, the wound was completely epithelialized. 
At this point, topical treatment with imiquimod was 
started, with application of cream to the washed and dried 
tumor surface and then washed off 12 hours after 
application 3 times per week. After 4 weeks of treatment, 
the verrucous plaques had decreased in size; however, 
formation of mild erythema and crust with oozing was 
observed on the tumor and the patient complained of 
local pain. Therefore, application of imiquimod was then 
stopped and the patient received oral administration of 
analgesics and topical application of antibiotics to the 
tumor. Over a 4-week period of treatment with analgesics 
and topical antibiotics, local pain, erythema, and crust 
slowly disappeared. At this point, administration of 
imiquimod was started again, with application of 
treatment 3 times per week over a period of 4 weeks. 
Treatment was well tolerated by the patient and no 
unwanted side effects occurred. After 3 months of 
treatment, the tumor was clinically resolved (Fig. 1B).
Case 2
A 75-year-old male developed painful hyperkeratotic 
plaques on the right aspect of his lower lip, which had 
persisted for more than 6 months (Fig. 3A). Prior to his 
visit to our hospital, the patient had been diagnosed with 
verrucous carcinoma based on the results of a histologic 
examination conducted at another hospital. Because the 
lesions progressed in size after the biopsy, he visited our 
hospital without treatment. The patient was a heavy 
smoker, but had no previous history of trauma or 
exposure to radiation.
Physical examination revealed verrucous plaques with 
fissuring on the right aspect of the lower lip. Micro-
scopically, the specimen showed marked parakeratosis, 
neoplastic proliferation, and downward invasion of epi-
dermal keratinocytes with a blunt border and a pushed- 
down, bulldozing appearance. Inflammatory cell infiltrates 
surrounding the tumor were also observed (Fig. 4).HB Kwon, et al
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Fig. 4. A biopsy specimen revealed marked parakeratosis, neo-
plastic proliferation, and downward invasion of epidermal kera-
tinocytes with a blunt border and a pushed-down, bulldozing
appearance (H&E, ×20).
Fig. 3. (A) Verrucous plaques with 
fissuring on the right aspect of the 
lower lip. (B) After treatment, all skin 
lesions disappeared.
Cryotherapy was performed. Specifically, a cotton stick 
containing liquid nitrogen was applied to the skin lesion 
for 2 seconds three times with an interval of five seconds 
in between each application. Within a few hours of 
treatment, hyperemia and swelling were obvious and 
edema and hyperemia increased slowly over a period of 
48 hours. The treated mucosa then became covered with 
a yellowish slough that separated after 7 days. The treated 
lesion healed completely within 14 days, at which point 
topical treatment with imiquimod was started, with 
application of cream 3 times per week. After 3 weeks of 
treatment, the verrucous plaques almost completely 
disappeared; however, formation of mild erythema and 
crust was observed on the tumor, without pain. Topical 
treatment with imiquimod was continued, with no additional 
side effects, and, after 7 weeks of treatment, this area was 
clinically resolved (Fig. 3B).
DISCUSSION
The natural history of verrucous carcinoma of the skin is 
marked by slow growth of a well-circumscribed tumor, 
which often shows a papillomatous surface. The tumor is 
typically located on the sole of the foot or elsewhere on 
the lower extremities; however, other locations, including 
the buttocks or the palm of the hand, have been reported
4. 
In 1981, Diaz-Pérez et al.
5 first reported lip verrucous 
carcinoma similar to the cases described. In addition, 
Krutchkoff et al.
6 reported that verrucous carcinoma on 
the lip constituted only 2.8% of all oral neoplasms. 
Although the cause of verrucous carcinoma is still unclear, 
it has been reported to have an association with earlier 
injuries and scars, as well as with chronic inflammation
3,7. 
Chewing tobacco, betel nuts, and dipped snuffs are also 
associated with development of verrucous carcinoma of 
the lip
2. Although the role of human papillomaviruses in 
development of verrucous carcinoma of the skin is still 
unclear, DNA of human papillomaviruses has been identified 
in such carcinomas
8,9. However, in a clinicopathologic 
study, Kao et al.
4 were unable to demonstrate the 
presence of virus particles in specimens. 
Treatment modalities for verrucous carcinoma include 
surgical excision, chemotherapy, cryosurgery, intralesional 
or iontophoretic methods, systemic retinoid therapy, and 
radiotherapy. Surgical excision is the treatment of choice 
for verrucous carcinoma. However, incomplete resection 
can result in accelerated tumor growth; therefore, care 
must be taken to fully remove all parts of the tumor. In 
addition, when surgical excision is considered, the size of 
the defect is often the most important factor because it is 
usually a strong indicator of the optimal method of 
reconstruction
10. A defect of approximately 30% of the 
upper or lower lip can be reconstructed by the primary 
closure due to the great elasticity of the lip
11. In our case, 
total excision was not performed because the tumor 
encompassed greater than 30% of the lower lip. If a wide 
excision had been performed in these cases, the defect 
would have required more complicated reconstructive Treatment of Verrucous Carcinoma of the Lower Lip with Topical Imiquimod (Aldara
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treatment, such as flap surgery.
Imiquimod, a toll-like receptor 7 agonist, is a patient- 
applied cream that is used in treatment of certain diseases 
of the skin, including various forms of skin cancer (basal 
cell carcinoma, Bowen’s disease, superficial squamous 
cell carcinoma, some superficial malignant melanomas, 
and actinic keratosis) as well as genital warts
11-16. The 
exact mechanism of imiquimod is not known; however, 
its effects are thought to be a result of augmentation of 
immune response through induction of interferon alfa
17.
Imiquimod has been used in conjunction with a carbon 
dioxide laser for treatment of perianal verrucous carci-
noma
18. In addition, Schalock et al.
19 described 2 cases of 
verrucous carcinoma of the foot, which were treated with 
imiquimod for more than 1 year.
We did not perform a biopsy after treatment; therefore, we 
cannot confirm that the tumor has been resolved. 
However, no further relapse has been observed for 30 
months since the last treatment.
In summary, here we describe two cases of rapidly 
growing oral verrucous carcinoma of the lip, which were 
treated with a combination of topical imiquimod and 
debulking therapy. There was no recurrence of the 
carcinoma for more than 3 months and the cosmesis was 
excellent. Taken together, these findings suggest that 
combination therapy of topical imiquimod and a debulking 
method may be useful for treatment of some cases of 
verrucous carcinoma.
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